Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
Open accessAbstract
Large 'real world' studies demonstrating the limited effectiveness and slow onset of clinical response associated with our existing antidepressant medications has highlighted the need for the development of new therapeutic strategies for major depression and other mood disorders. Yet, despite intense research efforts, the field has had little success in developing antidepressant treatments with fundamentally novel mechanisms of action over the past six decades, leaving the field wary and skeptical about any new developments. However, a series of relatively small proof-of-concept studies conducted over the last 15 years has gradually gained great interest by providing strong evidence that a unique, rapid onset of sustained, but still temporally limited, antidepressant effects can be achieved with a single administration of ketamine. We are now left with several questions regarding the true clinical meaningfulness of the findings and the mechanisms underlying the antidepressant action. In this Circumspectives piece, Dr Sanacora and Dr Schatzberg share their opinions on these issues and discuss paths to move the field forward.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In all reports, initial efficacy of memantine, lanicemine, and CERC 301 was either transient or inconsistent in larger studies.
“In all reports, initial efficacy was either transient or inconsistent in larger studies [97,103,144,145,146].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 96 · Cited by 160
Research works printed but not linked: 3
- Bergman SA (1999). Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 46: 10-20.
- McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2014). A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 10: 1-12.
- Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G et al (2012). The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 26: 663-690.
- Authors
- Sanacora, G., & Schatzberg, A. F.
- Affiliations
- Yale University (US)
- Stanford Medicine (US)
- Corresponding author
- Sanacora, Gerard
- Venue
- Neuropsychopharmacology
- Published
- 2014-09-26
- Volume
- 40
- Issue
- 2
- Pages
- 259-267
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC4443967
- OpenAlex
- W2094384948
- Cited by
- 160
- References
- 96
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 11 · 2023: 13 · 2022: 5 · 2021: 8 · 2020: 10 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 34 · 2015: 21 · 2014: 1
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-03-13)
- Open access
- bronze
- doi.org
- Locations
- Neuropsychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- J.B. and M.K. Pritzker Family Foundation
- National Institute of Mental Health (R01MH081211)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, major depressive disorder, mood disorders, antidepressant mechanism, proof-of-concept studies, antidepressant drug development, clinical meaningfulness
- MeSH terms
- Animals, Antidepressive Agents, Humans, Ketamine, Synaptic Transmission, Receptors, N-Methyl-D-Aspartate, Receptors, Opioid, mu, Excitatory Amino Acid Antagonists, Glutamic Acid, Mood Disorders, Substance-Related Disorders, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review